Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets

Pediatric Pulmonology

Volumn 40, Issue 1, 2005, Pages 72-80

  Binns Loveman, Karen M ^a   Kaplowitz, Mark R ^a   Fike, Candice D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic GMP; Nitric oxide pathway; Phosphodiesterase inhibitors; Pulmonary circulation; Pulmonary vascular resistance; Selective pulmonary dilation

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SILDENAFIL;

AMBIENT AIR; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CALCULATION; CATHETERIZATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME INHIBITION; HEART OUTPUT; HEMODYNAMICS; HYPOXIA; LUNG CIRCULATION; LUNG WEDGE PRESSURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANOXIA; CHRONIC DISEASE; CYCLIC GMP; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LUNG; PIPERAZINES; PULMONARY ARTERY; REFERENCE VALUES; SWINE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 21444456940     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20229     Document Type: Article

References (32)

1. Weinberger B, Wekss K, Heck DE, Laskin DL, Laskin JD. Pharmacologic therapy of persistent pulmonary hypertension of the newborn. Pharmacol Ther 2001;89:67-79.
2. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002;87:15-18.
3. Allen J, ATS Subcommittee AoP. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003;168:356-396.
4. Subhedar NV. Recent advances in diagnosis and management of pulmonary hypertension in chronic lung disease. Acta Paediatr [Suppl] 2004;444:29-32.
5. Brody CM, Whitney EG, Lamb S, Beall A. Cellular mechanisms of cyclic nucleotide-induced vasorelaxation. J Vasc Surg 1997;25: 390-397.
6. Barry EA, DeFelice AF, Papoian T. Viagra tablets. NDA #20-895. Review and evaluation of pharmacology and toxicology data. Rockville, MD: Center for Drug Evaluation and research of the US Food and Drug Administration; 1998. http://www.fda.gov/ cder/news/viagra.htm.
7. Zhoa L, Mason NA, Morell NW, Kojonazarov B, Sadykoz A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-428.
8. Erickson S, Reyes J, Bohn D, Adatia I. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. J Am Coll Cardiol [Suppl] 2002;39:402.
9. Keller RL, Hamrick SEG, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004;5:184-187.
10. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 2003;29:1996-2003.
11. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension in the newborn. Pediatr Pulmonol 2003; 36:529-535.
12. Fike CD, Kaplowitz MR. Chronic hypoxia alters nitric oxide dependent pulmonary vascular responses in lungs of newborn pigs. J Appl Physiol 1996;81:2078-2087.
13. Haworth SG, Hislop AA. Effect of hypoxia on adaptation of the pulmonary circulation to extra-uterine life in the pig. Cardiovasc Res 1982;16:293-303.
14. Sauzeau V, Derkinderen MR, Lehoux S, Loirand G, Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 2003;93: 630-637.
15. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003;107:3230-3235.
16. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger G. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45.
17. Fineman JR, Soifer SJ, Heymann MA. Regulation of pulmonary vascular tone in the perinatal period. Annu Rev Physiol 1995;57: 115-134.
18. Shaul PW. Regulation of vasodilator synthesis during lung development. Early Hum Dev 1999;54:271-294.
19. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;105: 1098-1102.
20. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MWH, Bloch KD, Zapol WM. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92:1702-1712.
21. Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. J Br Ophthalmol 2004;88: 306-307.
22. Fike CD, Aschner JL, Zhang Y, Kaplowitz MR. Impaired NO signaling in small pulmonary arteries of chronically hypoxic newborn piglets. Am J Physiol Lung Cell Mol Physiol 2004;286: L1244-L1254.
23. Jeffery TK, Wanstall JC. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension. J Cardiovasc Pharmacol 1998;32:213-219.
24. Jeffery TK, Wanstall JC. Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. Can J Physiol Pharmacol 2001;79:227-237.
25. Fike CD, Kaplowitz MR, Pfister SL. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am J Physiol Lung Cell Mol Physiol 2003;284:316-323.
26. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric oxide synthase activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 2002;15:44085-44092.
27. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, Clark MWH, Winkler JD, Bloch KD, Zapol WM. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29:1000-1005.
28. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105: 2398-2403.
29. Wilkins H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
30. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002;360:895-900.
31. Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004;55:413-418.
32. Dukarm RC, Morin FC III, Russell JA, Steinhorn RH. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatr Res 1998;44:831-837.